Angiotensin 1-7
Ang-(1-7) · ACE2 Downstream Peptide
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
Angiotensin-(1-7) is a well-characterized endogenous heptapeptide and the Mas-receptor agonist that forms the protective, counter-regulatory arm of the renin-angiotensin system, opposing angiotensin II. Its physiology rests on strong preclinical and mechanistic work, but human therapeutic evidence is limited to early-phase trials: the pharmaceutical formulation TXA-127 (talfirastide) reached small Phase 1-2 COVID-19 trials that confirmed safety but were neutral on their primary efficacy endpoints, and no formulation has ever been approved for any indication, so the marketed therapeutic use grades grade 2.
- FDA
- No approval for any indication. TXA127 (talfirastide) holds several FDA orphan-drug designations (pulmonary arterial hypertension, stem-cell engraftment, myelodysplastic syndrome, and rare muscular dystrophies) and a fast-track designation for Duchenne muscular dystrophy, all pre-approval.
- WADA
- Not listed on the WADA Prohibited List.
Reference only. Not medical advice.
What can go wrong
Only early-phase human data; very short half-life of minutes creates a delivery challenge; reversible bradycardia was reported as possibly related to infusion in one ICU patient.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Angiotensin 1-7. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
An endogenous heptapeptide generated by ACE2, angiotensin-(1-7) is the Mas-receptor agonist that forms the protective, counter-regulatory arm of the renin-angiotensin system, opposing the ACE/angiotensin II axis with signals associated with cardioprotective, anti-inflammatory, and anti-fibrotic effects. Its synthetic formulation TXA-127 (talfirastide) reached early-phase human trials, including COVID-19 ICU studies that showed safety but neutral efficacy, and no product is approved.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Angiotensin 1-7 is part of the protective arm of the blood-pressure (renin-angiotensin) system, counterbalancing the harmful, vessel-constricting Angiotensin II. Generated largely by the enzyme ACE2 and acting through the Mas receptor, it relaxes blood vessels and is anti-inflammatory, anti-fibrotic and tissue-protective, making it a target for cardiovascular and organ-protective therapy.
Angiotensin 1-7 is a seven-amino-acid peptide of the renin-angiotensin system, produced mainly by the enzyme ACE2 acting on angiotensin II, and signaling through a receptor called Mas. It forms the protective ACE2 to angiotensin 1-7 to Mas axis that opposes the classical damaging arm of the system.
- Type
- RAS peptide
- Length
- 7 amino acids
- Made by
- ACE2
- Receptor
- Mas
- Oral
- Not feasible
- Approved drug
- None
The Protective Arm Of The Blood-Pressure System, Still Unproven As A Drug
Angiotensin 1-7 is real, textbook cardiovascular physiology, which is both its strength and the reason to be careful about the gray-market version. It is the protective arm of the same hormone system that blood-pressure drugs like ACE inhibitors and ARBs target, opposing angiotensin II to produce vasodilation and anti-inflammatory, anti-fibrotic and anti-proliferative effects, with extensive preclinical evidence for protecting the heart, kidneys and lungs. It drew particular attention during COVID, since the enzyme that makes it, ACE2, is also the virus’s entry receptor. Pharmaceutical development is active, including a formulated version of the peptide and, tellingly, stabilized analogs and oral non-peptide drugs that mimic it. That last point is the honest core: angiotensin 1-7 itself has a very short half-life and is destroyed in the gut, so it cannot be taken orally, and despite decades of strong preclinical work there is no approved angiotensin 1-7 drug and only limited, early human efficacy data, including COVID trials that did not lead to approval. Sold gray-market as an injectable research peptide for cardiovascular and recovery purposes, it is unproven in humans and not even the form serious development is betting on.
Safety in detail
Human exposure so far comes from small early-phase trials, chiefly intravenous infusion in hospitalized COVID-19 and ICU patients, where it was generally well tolerated with no dose-limiting toxicity. It is an investigational agent, not an approved drug and not a dietary supplement, and no formulation is cleared for consumer or performance use.
- As a vasoactive peptide it can affect blood pressure, and its broad-population safety is not established outside trials.
- It remains investigational, without an approved product.
- Any consumer material would be gray-market and unverified.
- Not approved for any use.
Children and teenagers
Angiotensin 1-7 has no validated pediatric use and is an unapproved injected peptide affecting the cardiovascular hormone system. There is no appropriate pediatric use.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Angiotensin 1-7 reaches users through the gray-market research-peptide trade for cardiovascular and recovery purposes, but its serious commercial future lies in formulated versions, stabilized analogs and oral Mas-receptor drugs being developed by industry, not in the injectable native peptide.
How we got here
Angiotensin-(1-7) is a natural fragment of the renin-angiotensin system, first noted as a biologically active peptide in the late 1980s by Santos, Campagnole-Santos, and colleagues, and cemented in 2003 when Santos et al. identified it as the endogenous ligand of the Mas receptor, defining the protective ACE2/Ang-(1-7)/Mas arm that counter-regulates the ACE/angiotensin II/AT1 arm. As a therapeutic it was formulated as the synthetic peptide TXA127 (generic name talfirastide) and developed first by Tarix Pharmaceuticals / Tarix Orphan and later by Constant Therapeutics, chiefly for rare muscular dystrophies and fibrotic and hematologic conditions, collecting multiple FDA orphan-drug designations and a Duchenne fast-track designation. During the COVID-19 pandemic the same molecule was repurposed into small randomized ICU trials on the rationale that SARS-CoV-2 depletes ACE2 and thereby the protective Ang-(1-7) signal, but those trials confirmed safety without meeting efficacy endpoints, and to date no angiotensin-(1-7) product has been approved for any indication.
Angiotensin 1-7 emerged as scientists recognized a protective counter-regulatory arm of the renin-angiotensin system, defined by the enzyme ACE2 and the Mas receptor. Decades of preclinical work established its protective effects, and development advanced through formulated versions and COVID-era trials, while delivery limits pushed the field toward stabilized analogs and oral mimics.
The numbers behind the grade
- Type
- Angiotensin peptide
- Arm
- Protective (ACE2-Mas)
- Action
- Vasodilation, anti-fibrotic
- Stage
- Investigational
- Approved
- No
- Use
- Research
The people taking it
A scientifically important counter-regulatory peptide of the blood-pressure system, of interest in cardiovascular research but not a consumer product.
Angiotensin 1-7’s users are cardiovascular- and recovery-focused biohackers in the gray-market peptide community, alongside the researchers and companies pursuing its protective axis as a drug target.
Studied in research and early trials for cardiovascular protection and tissue repair as the protective counterpart to Angiotensin II; it has no approved consumer use.
Set against the alternatives
Angiotensin 1-7 is core cardiovascular physiology, the protective counterpart to the angiotensin II that blood-pressure drugs target. Among the protective peptides here it sits beside the cardiac peptide Apelin-13 and the tissue-protective ARA-290 and anti-fibrotic B7-33, all of which share strong preclinical promise and limited human proof. Its distinguishing feature is that the real drug development has largely moved past the native peptide to analogs and oral mimics.
What we do not know
- Whether boosting the protective Angiotensin 1-7 arm translates into real cardiovascular benefit.
- How to deliver such a short-lived peptide effectively.
- Which conditions its anti-fibrotic, anti-inflammatory effects could treat.
Legal status
Angiotensin 1-7 is an investigational peptide studied for cardiovascular and tissue-protective uses; it is not approved or marketed. Any consumer-facing material is research-use-only.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
There is no approved consumer route. It exists mainly as a research compound; given the limited human data, self-experimentation is not advisable.
Not produced as an approved drug for this use; any consumer-facing material is research-use-only, typically synthesized overseas in China, with no quality assurance and frequently no certificate of analysis.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Angiotensin 1-7.
- Timeline. We have not built the dated record of research and regulatory events.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
Sources
Angiotensin-(1-7) is the endogenous ligand for the G-protein-coupled receptor Mas, establishing the ACE2/Ang-(1-7)/Mas counter-regulatory axis (2003 landmark).
Randomized placebo-controlled seamless Phase 1-2 trial of Ang-(1-7) infusion in ICU COVID-19 patients (107 total) was safe but showed no significant difference in organ/oxygen-free days in the Phase 2 intention-to-treat analysis.
Randomized, double-blinded, placebo-controlled pilot study of TXA-127 in severe COVID-19 was terminated early, showed no difference in intubation, length of stay, or mortality, and no serious adverse events.
Comprehensive physiological review of the ACE2/Angiotensin-(1-7)/Mas axis and its cardioprotective, anti-inflammatory, and anti-fibrotic signaling.
Historical account of the discovery of Ang-(1-7) and Mas and the ~15-year gap before their interaction was revealed in 2003.
Rationale and safety background for evaluating Ang-(1-7)/Mas agonists in COVID-19, noting prior clinical use was safe and well tolerated without dose-limiting toxicity.
Urgent need for evaluating agonists of Ang-(1-7)/Mas axis, Int. J. Infectious Diseases / PMC
TXA127 (talfirastide) is a synthetic peptide identical to endogenous angiotensin-(1-7), developed by Tarix Orphan and later Constant Therapeutics, granted FDA orphan-drug status for pulmonary arterial hypertension, stem-cell engraftment, and myelodysplastic syndrome.
FDA granted Fast Track Designation to TXA127 (angiotensin 1-7) for Duchenne muscular dystrophy; effective in animal models but not approved.
Review of the ACE2/Ang-(1-7)/Mas axis as an emerging pharmacological target in pulmonary and fibrotic disease.
The studies that matter
Protective renin-angiotensin biology2000s-2010s
Established Angiotensin 1-7 and the ACE2-Mas axis as the counter-regulatory, protective side of the renin-angiotensin system.
Therapeutic candidates2010s-2020s
Formulations of Angiotensin 1-7 have been studied for cardiovascular protection, tissue repair and inflammatory conditions in early trials.
COVID-19 interest2020s
Because the virus uses ACE2, the ACE2-Angiotensin 1-7 axis drew research attention during the pandemic.